Cerezyme (imiglucerase) (Imiglucerase INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 40 U/mL

Cerezyme (imiglucerase) is an FDA-approved orphan drug manufactured by Sanofi Genzyme for the treatment of Gaucher Type I Disease, a rare genetic lysosomal storage disorder. It is administered intravenously and represents a breakthrough enzyme replacement therapy in the neurology and genetics therapeutic area.

Strength

40 U/mL

Pack Size

1 VIAL, GLASS in 1 CARTON (58468-4663-1) / 10 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

Sanofi Genzyme

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Cerezyme is indicated for patients with Gaucher Type I Disease, a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase (also called β-glucosidase). This enzyme deficiency leads to accumulation of glucocerebroside in macrophages throughout the body, resulting in hepatosplenomegaly, bone disease, anemia, thrombocytopenia, and fatigue. Cerezyme works through enzyme replacement therapy, providing exogenous imiglucerase to catalyze the hydrolysis of glucocerebroside, thereby reducing substrate accumulation and alleviating disease manifestations. The drug is suitable for patients of all ages with confirmed Gaucher Type I Disease diagnosis. Treatment with Cerezyme has been shown to reduce organomegaly, improve hematologic parameters, enhance bone density, and improve overall quality of life in affected patients. The typical patient population includes both pediatric and adult patients with symptomatic disease requiring therapeutic intervention.

Side Effects

Common adverse effects of Cerezyme include infusion-related reactions such as fever, chills, flushing, tachycardia, and hypotension, typically occurring during or shortly after intravenous administration. Other frequently reported side effects include headache, nausea, vomiting, diarrhea, and fatigue. Serious adverse events include anaphylaxis, severe hypersensitivity reactions, and development of anti-imiglucerase antibodies in some patients. Patients require baseline and periodic monitoring of liver and spleen size, hematologic parameters (hemoglobin, platelet count), bone density, and chitotriosidase levels. Infusion reactions necessitate premedication protocols and careful monitoring during administration.

Precautions & Warnings

Cerezyme is contraindicated in patients with known hypersensitivity to imiglucerase or any excipients. Caution is warranted in patients with history of hypersensitivity reactions or anaphylaxis. Pregnancy category C; use only if potential benefits justify risks to the fetus. Pediatric patients require dose adjustments based on body weight and careful monitoring for infusion reactions. Patients with renal or hepatic impairment should be monitored closely, though dose adjustments are not typically required. Pre-existing antibodies to imiglucerase may reduce drug efficacy. Patients should be screened for anti-imiglucerase antibodies before and during treatment.

Avoid Interactions

No significant drug-drug interactions have been formally documented with Cerezyme. However, concurrent use with other intravenous medications should be carefully managed to avoid incompatibilities. Patients receiving immunosuppressive therapy may have altered immune responses. No specific food or substance interactions are known. Cerezyme should not be mixed with other medications in the same intravenous line. Healthcare providers should review all concurrent medications and supplements with patients.

Frequently Asked Questions

Cerezyme is used to treat Gaucher Type I Disease, a rare genetic disorder where the body cannot properly break down certain fatty substances. It works by replacing the missing enzyme glucocerebrosidase, helping to reduce the accumulation of these substances in organs and tissues. This helps alleviate symptoms such as enlarged liver and spleen, anemia, and bone problems.

Cerezyme is administered as an intravenous infusion, typically given every two weeks. The dose is individualized based on patient body weight and disease severity, usually ranging from 2.5 to 60 units per kilogram. Each infusion is diluted in saline and administered over 15-60 minutes, depending on tolerance and institutional protocols.

Common side effects include infusion-related reactions such as fever, chills, flushing, and headache. Gastrointestinal symptoms like nausea, vomiting, and diarrhea may occur. Most infusion reactions are mild to moderate and can be managed with premedication and slower infusion rates. Serious reactions including anaphylaxis are rare but require immediate medical attention.

Cerezyme is manufactured by Sanofi Genzyme, a leading biopharmaceutical company specializing in rare genetic diseases and oncology.

Yes, Cerezyme is an FDA-approved orphan drug, designated for the treatment of Gaucher Type I Disease, a rare genetic disorder affecting fewer than 200,000 people in the United States. Orphan drug status provides regulatory incentives and market exclusivity to encourage development of treatments for rare diseases.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.